Stocks Clock Fourth...
Health Care: Drugs
Synageva BioPharma Corp (GEVA: NASDAQ)
$39.87 0.04 | 0.10%
05/17/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 14.95M | 2.10M | 26.72M | 15.18M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 14.95M | 2.10M | 26.72M | 15.18M |
| Selling, General, and Administrative Expenses | 17.40M | 9.27M | 5.78M | 5.52M |
| Research & Development | 37.35M | 17.85M | 0.00 | 0.00 |
| Operating Income before D & A (EBITDA) | -39.79M | -25.02M | 20.94M | 9.66M |
| Depreciation & Amortization | 4.58M | 1.03M | 99.00K | -12.00K |
| Interest Income | 72.00K | 4.67K | 71.00K | 366.00K |
| Other Income - Net | 0.00 | -258.54K | 0.00 | 8.97M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -44.30M | -26.31M | 20.91M | 19.01M |
| Interest Expense | 0.00 | 33.47K | 130.00K | 257.00K |
| Pre-Tax Income | -44.30M | -26.34M | 20.78M | 18.76M |
| Income Taxes | 0.00 | 0.00 | 925.00K | 6.45M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -42.95M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -42.95M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -42.95M | -25.31M | 19.95M | 12.30M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-42.95M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -42.95M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -1.90 | -8.58 | 4.45 | 2.75 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.90 | -8.58 | 4.45 | 2.75 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.90 | -8.58 | 4.45 | 2.75 |
| Basic Normalized Net Income/Share | -1.90 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -1.90 | -8.58 | 4.45 | 2.75 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.90 | -8.58 | 4.45 | 2.75 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.90 | -8.58 | 4.45 | 2.75 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.90 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with GEVA
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks At New 52-Week Highs...
- ContributorStocks At New 52-Week Highs...
Latest GEVA Headlines from TheStreet
- Synageva BioPharma Corp Enters Oversold Territory (GEVA) 05.10.13 | 12:05 pm
- GEVA Crosses Below Key Moving Average Level 05.01.13 | 11:05 am
- Top Insider Trades: AEGR GEVA DRI HNSN 01.16.13 | 09:01 am
- 5 Stocks Insiders are Scooping Up 01.09.13 | 12:01 pm
- Top Insider Trades: NCR PLCE GEVA LEI 01.09.13 | 09:01 am
- 5 Stocks Insiders Love Right Now 07.18.12 | 10:07 am
- Insiders Trading GEVA, GNOM, VPRT, HSON 07.16.12 | 09:07 am
- Insiders Trading DNKN, GEVA, HMPR, PGCG 06.29.12 | 09:06 am
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- 8 Stocks Rising on Monster Volume 02.29.12 | 03:02 pm
Press Releases for GEVA
- Late Onset LAL Deficiency (CESD) Literature Review Published In The Journal Of Hepatology - Business Wire 03.26.13 | 07:03 am
- Synageva BioPharma™ Reports 2012 Full Year Financial Results - Business Wire 03.11.13 | 04:03 pm
- Synageva BioPharma™ To Host 2012 Fourth Quarter And Full Year Financial Results Conference Call On March 11 - Business Wire 03.01.13 | 12:03 pm
- Synageva BioPharma™ Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2013 - Business Wire 02.28.13 | 06:02 am
- Synageva BioPharma™ To Present At The Cowen And Company 33rd Annual Health Care Conference - Business Wire 02.26.13 | 11:02 am
- Synageva BioPharma™ Initiates Dosing In Phase 3 Trial Of Sebelipase Alfa In Children And Adults With Late Onset LAL Deficiency - Business Wire 02.11.13 | 07:02 am
- Synageva BioPharma™ To Present At The Leerink Swann Global Healthcare Conference 2013 - Business Wire 02.06.13 | 04:02 pm
- Hepatology Publishes 12-Week Phase I/II Extension Study Data Of Sebelipase Alfa In Adults With Late Onset LAL Deficiency - Business Wire 02.04.13 | 04:02 pm
- Synageva BioPharma™ Highlights Data Presentations At The 9th Annual Lysosomal Disease Network (LDN) WORLD Symposium - Business Wire 01.30.13 | 04:01 pm
- Synageva BioPharma Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares - Business Wire 01.09.13 | 09:01 am
Partner Headlines for GEVA
- UPDATE: Piper Jaffray Lifts Synageva PT on Attractive Upcoming LAL-D Treatment - Benzinga 03.12.13 | 09:03 am
- UPDATE: Wedbush Securities Reiterates Outperform Rating, Raises PT on Synageva BioPharma Corp. - Benzinga 11.07.12 | 08:11 am
- Winning Trades Based on Analyst Ratings for June 25 - Benzinga 06.25.12 | 01:06 pm
- UPDATE: Morgan Stanley Initiates Synageva Biopharma with Buy, $76 PT - Benzinga 04.20.12 | 09:04 am
